Isotretinoin therapy and the incidence of acne relapse: A nested case-control study

British Journal of Dermatology

Volumn 157, Issue 6, 2007, Pages 1240-1248

  Azoulay, L ^a,b   Oraichi, D ^b   Berard A ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Acne; Isotretinoin; Predictors; Relapse

Indexed keywords

ANTI ACNE AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZOYL PEROXIDE; CLINDAMYCIN; DIANE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; RETINOIC ACID; RETINOID; TAZAROTENE; TETRACYCLINE;

ACNE; ADOLESCENT; ADULT; ARTICLE; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RELAPSE; RETREATMENT; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; URBAN AREA;

ACNE VULGARIS; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 36148999084     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08250.x     Document Type: Article

References (31)

1. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995 333 : 101 6.
2. Bérard A, Azoulay L, Koren G et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007 63 : 196 205.
3. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001 45 : S150 7.
4. Harms M, Masouye I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986 172 : 148 53.
5. Chivot M, Midoun H. Isotretinoin and acne - a study of relapses. Dermatologica 1990 180 : 240 3.
6. Layton AM, Knaggs H, Taylor J et al. Isotretinoin for acne vulgaris - 10 years later: a safe and successful treatment. Br J Dermatol 1993 129 : 292 6.
7. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993 186 : 123 8.
8. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993 129 : 297 301.
9. Shahidullah M, Tham SN, Goh CL. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol 1994 33 : 60 3.
10. White GM, Chen W, Yao J et al. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998 134 : 376 8.
11. Ng PP, Goh CL. Treatment outcome of acne vulgaris with oral isotretinoin in 89 patients. Int J Dermatol 1999 38 : 213 16.
12. Lehucher-Ceyrac D, de La SP, Chastang C et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999 198 : 278 83.
13. Al-Mutairi N, Manchanda Y, Nour-Eldin O et al. Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol 2005 4 : 369 73.
14. Haryati I, Jacinto SS. Profile of acne patients in the Philippines requiring a second course of oral isotretinoin. Int J Dermatol 2005 44 : 999 1001.
15. Quereux G, Volteau C, N'Guyen JM et al. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006 212 : 168 76.
16. Statistiques annuelles. Régie de l'assurance maladie du Québec. Quebec : Government of Quebec, 1997.
17. World Health Organization. International Classification of Diseases, 9th Revision (ICD-9). Geneva : World Health Organization, 1977.
18. Tamblyn R, Lavoie G, Petrella L et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 48 : 999 1009.
19. Tamblyn R, Reid T, Mayo N et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000 53 : 183 94.
20. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995 142 : 428 36.
21. Azoulay L, Oraichi D, Berard A. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006 62 : 667 74.
22. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004 61 : e59.
23. Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia, PA : Lippincott-Raven, 1998.
24. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003 168 : 49 53.
25. Ho V, Schachter D, Miller R. Acne management for the 90s: current treatment guidelines. Can J Diagnosis 1995 12 (Suppl. 1 25.
26. Tan JK. Perspectives on isotretinoin and the Canadian Consensus Guidelines on treatment of acne. Skin Therapy Lett 2000 6 : 1 4.
27. Madden WS, Landells ID, Poulin Y et al. Treatment of acne vulgaris and prevention of acne scarring: Canadian consensus guidelines. J Cutan Med Surg 2000 4 (Suppl. 1 S2 13.
28. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999 282 : 1458 65.
29. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002 46 : 505 9.
30. Wert S. Identification and management of oral isotretinoin use inconsistent with product labeling. Manag Care Interface 2003 16 : 41 3.
31. Chen K, White TJ, Juzba M, Chang E. Oral isotretinoin: an analysis of its utilization in a managed care organization. J Manag Care Pharm 2002 8 : 272 7.